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Defining growth factor requirements for progenitors
facilitates their characterization and amplification.
We characterize a peripheral nervous system embry-
onic dorsal root ganglion progenitor population using
in vitro clonal sphere-formation assays. Cells differ-
entiate into glial cells, smooth muscle/fibroblast
(SM/Fb)-like cells, andneurons.Genetic andpharma-
cologic tools revealed that sphere formation requires
signaling from the EGFR tyrosine kinase. Nf1 loss of
function amplifies this progenitor pool, which be-
comes hypersensitive to growth factors and confers
tumorigenesis. DhhCre;Nf1fl/fl mouse neurofibromas
contain a progenitor population with similar growth
requirements, potential, and marker expression. In
humans, NF1 mutation predisposes to benign neu-
rofibromas, incurable peripheral nerve tumors.
Prospective identification of human EGFR+;P75+
neurofibroma cells enriched EGF-dependent sphere-
formingcells. Neurofibromaspherescontainglial-like
progenitors that differentiate into neurons and SM/
Fb-like cells in vitro and form benign neurofibroma-
like lesions in nude mice. We suggest that expansion
of an EGFR-expressing early glial progenitor contrib-
utes to neurofibroma formation.
INTRODUCTION
Schwann cells are peripheral nerve glia derived from the neural
crest, a multipotent cell population that delaminates from the
dorsal neural tube at E9 in the mouse. In addition to Schwann
cells, rodent trunk level crest cells in vivo give rise to neurons
of the peripheral nervous system (PNS), including those of the
dorsal root ganglion (DRG), melanocytes, and endoneurial fibro-
blasts, in vitro and in vivo (Baroffio et al., 1988; Chen and Lech-
leider, 2004; Fernandes et al., 2004; Ito et al., 1993; Joseph et al.,
2004; Morrison et al., 1999; Shah et al., 1996; Stemple and658 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier InAnderson, 1992). Growth factor signaling is broadly implicated
in the maintenance of progenitor populations. In neural crest,
combinations of Wnt and BMP suppress neural crest stem cell
differentiation and maintain multipotency (Kleber et al., 2005;
Lee et al., 2004), and notch and BMP2 signals influence gliogenic
and neurogenic fate determination (Lo et al., 2002; Morrison
et al., 1999).
The epidermal growth factor receptor (EGFR) has been specif-
ically implicated in central nervous system progenitor expansion.
Ligand (EGF) exposure confers multipotency to CNS subventric-
ular zone progenitors at the transit-amplifying stage (Doetsch
et al., 2002; Fernandes et al., 2004; Reynolds and Weiss,
1992). EGFR signaling influences fate choices and chemotaxis
of neural progenitors (Aguirre et al., 2005; Burrows et al., 1997;
Lillien and Wancio, 1998). EGF has been included in culture me-
dium for neural progenitors not only in the CNS but also in PNS
boundary cap cells and dermal neural crest-derived progenitors
(Fernandes et al., 2004; Hjerling-Leffler et al., 2005; Maro et al.,
2004; Sieber-Blum et al., 2004), yet the effects of EGFR and its
ligands have not been analyzed in DRG or peripheral nerve
progenitors.
Neural crest cells develop into Schwann cell precursors be-
tween E11 and E13 in mouse sciatic nerve, immature Schwann
cells by E15, and Schwann cells by E18 (Dong et al., 1999; Jes-
sen and Mirsky, 2005). Progenitors identified after the establish-
ment of the dorsal root ganglia (DRG) and the peripheral nerve
have more limited self-renewal and differentiation potential
than neural crest stem cells (Bixby et al., 2002; Kleber et al.,
2005; Nagoshi et al., 2008). Products of the neuregulin-1
(Nrg-1) gene, acting through the receptor tyrosine kinase hetero-
dimer ErbB2/3, promote survival of Schwann cell precursors and
their differentiation into S100b+ Schwann cells (Dong et al., 1999;
Leimeroth et al., 2002; Shah et al., 1996). The roles of most
growth factors have not been analyzed in the developing PNS,
especially in the neural crest-Schwann cell precursor transition.
The most common PNS tumor is the neurofibroma, hallmark of
the inherited disorder neurofibromatosis type 1 (NF1) (Rasmus-
sen and Friedman, 2000; Carroll and Ratner, 2008). Biallelic
NF1 mutations have been detected in neurofibroma Schwann
cells, implying that the Schwann cell lineage drives neurofibroma
formation (Serra et al., 2001). Multiple Cre recombinase driverc.
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cause in vivo GEM-neurofibroma formation share expression at
the Schwann cell precursor or boundary cap stages of Schwann
cell development, placing the neurofibroma cell of origin subse-
quent to the neural crest stage (Joseph et al., 2008; Wu et al.,
2008; Zheng et al., 2008; Zhu et al., 2002). It is debated whether
the neurofibroma initiating cell is a committed glial cell, a dediffer-
entiated Schwann cell, or a postcrest progenitor cell.
Failure of cellular differentiation and subsequent augmentation
of a progenitor population may provide a basis for tumorigenesis
(Jordan et al., 2006). Here we tested the hypothesis that the ex-
pression of EGFR defines a normal peripheral nerve glial progen-
itor population susceptible to Nf1 mutation, because 1%–2% of
cells in neurofibromas express the Schwann cell marker S100b
and the EGFR, which is not expressed by Schwann cells (DeClue
et al., 2000). Also, some cells in neurofibroma tissue sections ex-
press the stem cell marker CD34 (Khalifa et al., 2000). In addition,
E12.5 Nf1/ DRG cultures are abnormally abundant in EGFR+
cells expressing the Schwann cell precursor marker Blbp/Fabp7
(DeClue et al., 2000; Miller et al., 2003).
We show that Nf1 loss in mouse expands numbers of EGFR-
dependent peripheral progenitor cells and confers tumorigenic
capacity. Additionally, neurofibromas in the DhhCre;Nf1fl/fl
Figure 1. Peripheral Nervous System Pro-
genitors Are Sensitive to Nf1 Mutation and
Can Be Clonally Expanded
(A) Primary sphere formation from embryonic
(E12.5) DRG is amplified in Nf1/ (white bar) ver-
sus wild-type (black bar). Gray bar is Nf1+/.
(B) Neonatal (P2) mutant nerves yield primary
spheres, and wild-type do not; adult (P120) nerves
do not contain sphere-forming cells.
(C) Secondary sphere formation does not differ be-
tweenwild-typeandNf1mutant embryonicspheres.
(D) Primary neonatal spheres do not make sec-
ondary spheres.
(E–H) Mixing eGFP+ and eGFP cells from disso-
ciated wild-type or Nf1/ spheres plated at clonal
density give rise to unlabeled (E and F) or eGFP+
(G and H) single-color spheres.
(I–N) All nuclei (DAPI, false-colored red, [J] and
[M]) found in green spheres are within eGFP+ cells
(green, [I] and [L]) for wild-type (I–K) and mutant
(L–N); image overlay, (K) and (N).
(O) Limiting dilution shows increasing percentage
of single-color spheres. *p < 0.05, t test. Data are
shown as mean ± standard error of the mean.
model contain multipotent progenitors.
Finally, EGFR expression defines and al-
lows isolation of tumorigenic progenitors
from primary human neurofibromas.
RESULTS
Loss of Nf1 Leads to an Increase in
EGF-Dependent Sphere Formation
in the Developing PNS
Studies of various neural progenitors
have demonstrated the utility of the
in vitro sphere assay to assess self-renewal capability of a cell
population (Fernandes et al., 2004; Joseph et al., 2008; Reynolds
and Weiss, 1992). We dissociated E12.5 DRG of wild-type,
Nf1+/, and Nf1/ embryos and cultured the suspension under
sphere conditions defined for crest-derived progenitors (Fer-
nandes et al., 2004). Nf1/ DRG cell preparations gave rise to
spheres in the presence of EGF and bFGF at a rate of about
1:700 by 14 days, significantly higher than wild-type and Nf1+/
DRG cell suspensions (approximately 1:3000; p < 0.05,
Figure 1A). Postnatal day 2 (P2) and 120 (P120) sciatic nerves
were dissociated and plated in sphere-forming conditions.
Nf1+/ P2 nerve cells generated primary spheres, but wild-type
cells did not; at P120, cells from neither genotype yielded
spheres (Figure 1B). E12.5 DRG-derived spheres were dissoci-
ated to single-cell suspension and replated. Cells of all
genotypes formed secondary spheres, and the frequency of
formation was not statistically different among genotypes
(Figure 1C). Cells from spheres derived from embryonic DRG
from all genotypes could be passaged for at least ten genera-
tions. P2 Nf1+/ spheres, in contrast, failed to give rise to sec-
ondary spheres (Figure 1D). Early postnatal Nf1+/ nerves con-
tain EGFR+;P75+ cells (Wu et al., 2006) and may be the primary
sphere-forming cells at P2. The data imply that the number ofCell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 659
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self-renewal capacity of mutant cells is unaltered.
A widely accepted measure of cell self-renewal is testing ca-
pability of sustained clonal expansion. To test whether clonal
growth accounts for sphere formation, purified tertiary spheres
from wild-type and Nf1/ embryos were transduced with lenti-
viral eGFP, dissociated, and plated at limiting densities with
equal numbers of unlabeled cells. All spheres were clonal, as
cells were either fluorescent (green) or nonfluorescent (white)
when plated at densities of 250 cells/cm2 or lower (Figures 1E–
1H and 1O). Higher plating densities yielded colonies that con-
tained both fluorescent and nonfluorescent cells (data not
shown). Nuclear counterstain with DAPI (false-colored red) con-
firmed that all nuclei in newly forming spheres at clonal density
were exclusively eGFP+ or negative at low density (Figures
1I–1N). Clonal spheres from both genotypes could be dissoci-
ated and replated, giving rise to secondary low-density spheres
Figure 2. Embryonic Spheres Express Crest
andGlialMarkers; EGFRSignaling Is Critical
for Self-Renewal
(A and B) Expression of crest markers (A) and glial
lineage markers (B) by RT-PCR in wild-type (WT
Sph.) and Nf1/ (Nf1/ Sph.) spheres. E13NT(+)
refers to E13 neural tube and surrounding tissue,
a positive control. No template was added in reac-
tions corresponding to lanes labeled H2O.
(C–E) Spheres derived from wild-type (shown),
Nf1+/, and Nf1/ embryonic DRG contain cells
that express both P75 ([C], green) and EGFR
([D], red). (E) Merged image with DAPI (blue).
(F) Wild-type (black bars) and Nf1/ (white bars)
secondary sphere formation at varying doses of
EGF, bFGF, or both.
(G) Secondary sphere formation is blocked by er-
lotinib (white bars), an EGFR tyrosine kinase inhib-
itor compared to DMSO control (black bars), in
wild-type and Nf1/ spheres.
(H) Immunoprecipitation western blot indicating
downregulation of phospho-EGFR (pEGFR) after
treatment with erlotinib.
(I) The Wa2 EGFR mutation decreases the number
of sphere-forming cells in the embryonic DRG
(white bar) versus wild-type (black bar); secondary
sphere formation is shown.
(J) Wild-type and Nf1/ spheres express Egfr and
multiple ligands by RT-PCR. *p < 0.05; #p < 0.001
compared to EGF and bFGF alone, paired t test;
0.2 ng/ml EGF + bFGF is significant (#p < 0.001)
in Nf1/ versus wild-type (WT). Data are shown
as mean ± standard error of the mean.
(data not shown), indicating that spheres
form by expansion of single-cell clones,
not by cell aggregation. In conjunction
with our ability to passage spheres for
at least ten passages in vitro, the data in-
dicate that embryonic spheres contain
clonogenic self-renewing cells.
To correlate the phenotype of sphere
cells with the stages of development rele-
vant to the embryonic DRG, we examined
expression of a panel of crest and glial lineage markers using RT-
PCR. Wild-type and Nf1/ spheres express the neural crest
markers Twist, Nestin, Wnt5a, P75, and Sox9 (Figure 2A).
Spheres from both genotypes expressed the glial markers
Sox10, Mpz, Blbp (Fabp7), Dhh, and Gfap (Figure 2B). This
may reflect that spheres contain cells representative of neural
crest and/or immature glia, or an intermediate cell.
Sphere formation medium contains EGF and bFGF, implying
that receptors for one or both of these factors are present on
cells. We plated single spheres derived from wild-type, Nf1+/,
and Nf1/ DRG and assayed EGFR and P75 (a neural crest lin-
eage marker) immunoreactivity. Spheres from all genotypes con-
tained cells that coexpressed EGFR and P75 (Figures 2C–2E). All
spheres analyzed contained EGFR+;P75+ cells (n = 8 spheres
from each of three embryos per genotype).
To further characterize the external signals required for pro-
genitor expansion, we plated dissociated cells from purified660 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc.
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and Nf1/ sphere formation were significantly increased when
cultured with both factors versus either factor alone
(Figure 2F). Additionally, Nf1/ sphere-forming cells expanded
(7.7-fold increase) when cultured in EGF and bFGF at low con-
centration (0.2 ng/ml) as compared to wild-type (2.3% sphere
formation versus 0.3%), suggesting higher sensitivity to growth
factor-induced progenitor expansion. Spheres were maintained
at saturating concentrations of growth factors (20 ng/ml) for sub-
sequent experiments.
Sphere formation was impaired when cells from dissociated
primary spheres were subjected to 3 mM erlotinib (Figure 2G),
which blocks EGFR tyrosine kinase activity (Norman, 2001).
We confirmed the action of erlotinib on EGFR activity by western
blot (Figure 2H). We also used a genetic approach to assess the
degree to which EGFR activity drives sphere formation in the em-
bryonic DRG. We generated spheres from E12.5 DRG from mice
heterozygous for the EGFR mutation Waved-2 (Wa2/+) and their
wild-type littermate controls. Cells from the DRG of these mu-
tants showed a 3-fold reduction in sphere formation versus
wild-type, which was maintained even when spheres were pas-
saged, as secondary sphere formation is quantified in Figure 2I.
Thus, EGFR function is necessary for normal sphere formation.
The elevated response to low concentrations of EGF in Nf1/
cells suggested that they may release additional EGFR ligands,
which could act in an autocrine fashion. We examined whether
EGFR ligands were being synthesized by sphere cells by RT-
PCR. Cells from both wild-type and mutant spheres express
mRNA transcripts for Amphiregulin, Betacellulin, Tgf-a, HB-Egf,
and Epiregulin (Figure 2J). The relevance of these factors re-
mains to be determined.
Differentiation Potential of Nf1 Mutant Progenitors
As a defining characteristic of stem cells and progenitor cells is
their ability to differentiate along multiple lineages, we tested
whether cells in spheres from wild-type or Nf1/ embryonic
DRG showed multilineage differentiation. Cells from clonally de-
rived spheres were plated in serum in the absence of supple-
mental EGF and bFGF. Lineage differentiation markers were
not expressed in growing spheres or directly after plating (see
Figures S1A, S1C, and S1E, left panels, available online). In
some experiments, we monitored spontaneous differentiation.
In other experiments, we directed differentiation according to
previous reports (see the Experimental Procedures) by exposing
cells from spheres to lineage-specific growth factors after plating
in neurogenic, smooth muscle/fibroblastic, or gliogenic condi-
tions. Both wild-type and Nf1 mutant spheres formed Schwann
cells with cytoplasmic S100b expression, bipolar morphology,
and elongated nuclei (Figures S1A, right panels, and S1B). Cells
from both genotypes differentiated into SM/Fb-like cells, as as-
sayed by smooth muscle actin (SMA) immunoreactivity and large
round nuclei with a flattened, fibroblastic morphology (Figure
S1C, right panels, and S1D). When placed into neurogenic con-
ditions, wild-type cells very rarely expressed neuron-specific
b-tubulin (b-Tub). Cells from Nf1/ sphere cultures generated
many b-Tub+ cells with large cell bodies and long neurites
(Figure S1E, right panels). Of spheres that contained positive
cells, there was a 10-fold increase in the number of b-Tub+ cell
in Nf1/ spheres versus wild-type spheres (2.9% versusCe0.27%, respectively, Figure S1F) in the spontaneous format.
The cued paradigm also showed a neurogenic bias for the
Nf1/ spheres (2.1% versus 0.7%, respectively, Figure S1F).
Neurons also expressed neurofilament (NF-M, inset,
Figure S1E). We were unable to stimulate pigmentation by cells
from either genotype, although neural crest cells from mouse
E9.5 showed robust pigmentation under the same conditions
(data not shown). We conclude that wild-type cells from embry-
onic DRG-derived spheres differentiate into Schwann cells and
smooth muscle fibroblasts and infrequently into neurons. In con-
trast, Nf1 mutant cells appear less restricted.
To provide additional evidence supporting the ability of sphere
cells to differentiate into neurons and glia, we used an avian xe-
nograft assay of neural crest cell differentiation. Sphere cells,
wild-type and Nf1/, migrated to the DRG and peripheral nerve.
After in ovo differentiation, most cells express the Schwann cell
marker myelin basic protein (MBP), with some cells expressing
the neuronal marker NeuN within the DRG (Figure S2).
Nf1/ Spheres Give Rise to Subcutaneous
Tumors in Nude Mice
To assess the tumorigenic capacity of cells within spheres, we
injected dissociated sphere culture cells subcutaneously into
the flanks of nude mice. No lesions formed after injection of
wild-type cells (n = 11, 1.0  5.0 3 105 cells per injection) even
after 18 weeks. Nf1 mutant spheres were dissociated and in-
jected (1  1.5 3 105 cells per injection) and formed neurofi-
broma-like lesions in 11 of 21 injections (Figures 3A–3C). We
observed regions reminiscent of neurofibroma following hema-
toxylin and eosin staining of tissue sections (Figure 3D), contain-
ing occasional mast cells and cells with elongated nuclei
(presumptive Schwann cells or fibroblasts). No features of malig-
nancy (hypercellularity, failure to differentiate), necrosis, or
edema were observed. Tumor areas were close to nerve fibers,
as evident by neurofilament (Figure 3E) and S100b (Figure 3F)
staining. Some cells were S100b+, bipolar Schwann-like cells
(Figure 3G).
Prospective Identification of Human EGFR+
Neurofibroma Tumorigenic Cells
The mouse data demonstrate that the loss of Nf1 leads to an in-
crease in EGFR+ progenitors that can be isolated, expanded as
spheres, and are tumorigenic in nude mice. To test if human neu-
rofibromas contain similar cells, we plated primary neurofibroma
cells in medium containing EGF (20 ng/ml) and bFGF (40 ng/ml)
on low-binding plastic dishes and observed selective expansion
of cells that grew as floating spheres (Figure 4A). When grown on
tissue culture plastic dishes, spheres formed as attached colo-
nies, allowing for accurate quantification of growth (Table S1).
We stained cells from colonies replated on chamber slides. As
shown in Figures 4B–4E, we identified EGFR+;P75+ cells (n = 3
experiments, less than 2% total cells were double positive). To
test for EGF dependence of colony formation, we plated 43 104
primary neurofibroma cells per well in triplicate using a 24-well
plate cells in human sphere medium in the presence or absence
of 20 ng/ml EGF. In this case, cells were plated onto tissue cul-
ture plastic so that cells attached to the uncoated plastic for
quantification. Fourteen days later, colony (attached sphere)
formation was scored. In three experiments in triplicate wellsll Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 661
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(A) Tumor formation following subcutaneous injections of wild-type or Nf1/ sphere cells.
(B) Tumor (*) found under reflected skin (delineated by arrowheads) in mouse injected with mutant cells. Associated nerve (black arrow) and blood vessel (white
arrow) are visible.
(C) Dissected tumor; ruler divisions indicate 1 mm intervals.
(D and E) (D) Hematoxylin and eosin (H&E) staining of tumor section. Arrowhead indicates injection site. Tumor area is indicated by arrow, and box shows region
depicted in separate sections in (E)–(G). Immunohistochemistry showing neurofilament (NF-M)+ nerve bundles ([E], brown staining, arrow) in close proximity to
tumor region (*bounded by dotted line).
(F) Tumor region (*bounded by dotted line) contains some S100b+ cells (arrowhead) and associated nerve bundle is S100b+ (arrow).
(G) High magnification of S100b+ cell within tumor region (arrow). Blue is hematoxlyin counterstain in (E)–(G). Scale bars, (D), 200 mm; (E and F), 50 mm; (G), 20 mm.from two different patient tumors, in the presence of EGF, an av-
erage of 43 colonies per well formed, 8-fold higher than in the
absence of EGF (Figures 4F–4I). When cells were plated in
EGF together with the EGFR function-blocking antibody Cetux-
imab, an average of only four colonies per well appeared (Figures
4H and 4I). Similarly, when plated in EGF with the EGFR antago-
nist erlotinib (Tarceva; OSI-774), an average of four colonies per
well formed (data not shown). Thus, human neurofibroma cell
colony (sphere) formation is responsive to EGF and dependent
on EGFR activity.
We tested whether EGFR+ cells could be prospectively iso-
lated from human neurofibroma. We analyzed the coexpression
of EGFR and P75 surface markers by flow cytometry on cells
from aliquots of primary neurofibroma cells dissociated and
then frozen. The EGFR+;P75+ cells also expressed a stem cell
marker, CD34 (Figures 4J–4L), previously shown to be ex-
pressed in neurofibroma tissue sections (Khalifa et al., 2000).
The average final percentage of live cells that express all three662 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inantigens is 1.3%; all EGFR+;P75+ cells also express CD34
(data from two tumors from separate patients, sorted twice
each). We repeated this analysis on two additional independent
patient samples, and sorted live double-positive cells for culture
in the sphere-forming assay. The sorted double-positive popula-
tion showed 4- to 5-fold enrichment in primary colony-forming
cells as compared to bulk, unsorted cells, and depletion of the
EGFR+ lineage (P75+) cells from the same patients prevented
sphere formation. While bulk cells were rapidly depleted of
sphere-forming potential, the EGFR+;P75+ sorted cells retained
this capacity through tertiary passage (Figure 4M). Thus, EGFR
expression correlates with enrichment of human neurofibroma
sphere-forming capacity.
Expression of CD34 raised the possibility that cells were
blood-derived circulating progenitors similar to hematopoietic
stem cells found in muscle tissue. To exclude this possibility,
we performed cobblestone area-forming cell assays (CAFCs),
a classic in vitro hematopoietic stem cell/progenitor assayc.
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nies after 2 weeks; these did not possess hematopoietic mor-
phology; in the CAFC assay, very rarely CNS neural progenitors
will form colonies with a nonhematopoietic morphology (H.G.,
unpublished data). We incubated sorted EGFR+;P75+;CD34+
cells from a second patient neurofibroma in growth factor con-
taining methylcellulose medium for 10 days. In this definitive
hematopoetic stem and progenitor assay system, no neurofi-
broma cells formed colonies (data not shown). Thus, EGFR+;
P75+;CD34+ cells do not contain bone marrow stroma-depen-
dent hematopoietic stem or progenitor cells.
We have as yet failed to grow sorted EGFR+;P75+;CD34+ cells
under clonal conditions and have thus been unable to test
whether the triple-positive cells meet this criterion to be defined
as a stem cell; indeed, the inability to maintain spheres for more
than three passages suggests that they might resemble progen-
itors rather than stem cells. We first examined bulk neurofibroma
Figure 4. Human Neurofibromas Contain
EGFR+;P75+ Cells that Form Spheres in an
EGF-Dependent Manner
(A) Floating spheres derived from primary neurofi-
broma.
(B–E) Confocal images showing human spheres
containing P75+ (red) and EGFR+ (green) cells
(blue is DAPI). Rotated orientations of cell indi-
cated by arrow in (B) and (C) is in XY, (D) is XZ,
and (E) is YZ. Sphere formation conducted on
tissue culture plastic gives a clearly quantifiable
assay.
(F–I) Formation of attached spheres in the pres-
ence of EGF ([G], white bar in [I]) or absence of
EGF ([F], black bar in [I]) and after application of Ce-
tuximab, an inhibitor of EGFR ([H], gray bar in [I]).
(J–L) FACS analysis showing live cells (7-AAD-neg-
ative, R1, [J]), P75+ cells (R2, [K]), and CD34+;
EGFR+ cells from R2 (R3, [L]).
(M) FACS sorting to yield EGFR+;P75+ cells and
plating in sphere medium show enrichment of pri-
mary sphere formation in two patients. EGFR+;
P75+, Pt 1 = patient 1, EGFR+; P75+, Pt 2 = patient 2
(red and pink lines, respectively), compared with
EGFR;P75+ cells from the same patients (green
and gold lines) as well as bulk unsorted neurofi-
broma cells (averaged from three additional pa-
tients, blue line). *p < 0.05, paired t test. Scale
bars, (A) and (F)–(H), 100 mm; (B), 20 mm. Data are
shown as mean ± standard error of the mean.
tissue for progenitors, using the Schwann
cell precursor marker BLBP (FABP-7).
Both P75+;BLBP+ and EGFR+;BLBP+
cells were observed (Figures 5A and
5C). We confirmed CD34 and P75 ex-
pression in EGFR+ cells (Figures 5B and
5D). To assess whether spheres contain
neural crest cells, we examined spheres
from neurofibromas for expression of
various known crest markers. In addition
to BLBP, RT-PCR of neurofibroma-de-
rived EGFR-dependent spheres revealed
expression of mRNAs encoding the neu-
ral crest markers P75, SOX9, and TWIST and the stem cell
marker CD34 (Figure 5E).
The expression of these markers is associated with neural
crest and/or early glial lineage progenitor cells. Spheres do not
contain SMA+ or b-tubulin+ nonglial lineage cells (Figures 5G
and 5H) but can be differentiated in vitro to SMA+ SM/Fb-like
cells (Figure 5K) and b-tubulin+ (Figure 5L) and neurofilament+
(Figure 5M) neurons. They also became elongated and ex-
pressed cytoplasmic S100b as do Schwann cells after exposure
to gliogenic conditions (Figure 5J). However, this marker is ex-
pressed in sphere cells prior to differentiation (Figure 5F). Con-
sistent with the expression of early crest markers, differentiation
did not yield MBP immunoreactivity, a later marker of Schwann
cell differentiation, even though cultured normal human
Schwann cells were MBP+ (data not shown). When injected
into nude mice (1.0 – 2.0 3 105 cells/injection; three of six injec-
tions from three independent patients), human spheres grewCell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 663
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Differentiation and Benign Lesion Formation
(A–D) Cells from human tumors are double positive for P75 and BLBP (A), EGFR and CD34 (B), BLBP and EGFR (C), and EGFR and P75 (D). Arrowheads indicate
double-positive cells in each panel.
(E) RT-PCR showing expression of crest (SOX9, TWIST) and glial (BLBP) markers prior to differentiation. Data are representative of spheres derived from tumors
from two patients.
(F–M) Primary spheres derived form neurofibroma contain S100b+ (F) cells, but cells do not express SMA (G) or b-tubulin (b-Tub, [H]). After differentiation, cells
from spheres express S100b like Schwann cells (I and J), SMA like SM/Fb-like cells (I and K), or b-Tub (I and L) and neurofilament (NF-M) (M)-like neurons. Quan-
tification reflects differentiation of primary spheres derived from three independent patient tumors.
(N–Q) Neurofibroma-derived spheres give rise to benign lesions in vivo. (N) Hematoxylin and eosin staining of paraffin-embedded lesion. Lesions contain Mib1+
proliferating cells (O), S100b+ cells (P), and mast cells identified by toluidine blue (Q), indicated by arrowheads. Scale bars, (A)–(D), 20 mm; (F)–(H), 10 mm; (J)–(M),
20 mm; (N), 100 mm; (O)–(Q), 50 mm. Blue in (A)–(D), (F)–(H), and (J)–(M) is DAPI (nuclei). Data are shown as mean ± standard error of the mean.slowly (masses less than 3 cubic mm by 8–12 weeks) as benign
lesions containing S100b+ cells, mast cells, and rare Mib1+
cells (Figures 5N–5Q). Only at a 10-fold increase in cell number
(1.0 – 2.0 3 106 cells/injection; six of eight) did injection of nor-
mal human Schwann cells cause growths of similar size. Hema-
toxylin and eosin staining of sections from normal cell grafts
showed homogeneous S100b+ cells with microcysts containing
myxoid material. No mast cells were observed (data not
shown). Thus, EGFR-expressing multilineage progenitors are
present within neurofibroma-derived spheres, can be enriched
prospectively, and grow as a mixed cell population in athymic
nu/nu mice.664 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier IncDhhCre;Nf1fl/fl GEM-Neurofibroma Contains
EGF-Dependent Progenitors
To determine whether EGFR-dependent progenitors are present
in a mouse neurofibroma, we studied the DhhCre;Nf1fl/fl mouse
(Wu et al., 2008). EGFR+;P75+ cells were visualized by immuno-
fluorescence in GEM-neurofibroma sections (Figures 6A–6C). To
assess the presence of progenitors, we plated dissociated tumor
cells into medium permissive for sphere formation. Spheres
grew within 10–14 days (Figure 6D). Due to large amounts of
collagenous debris (even after filtering), quantification of cell
number at plating was not reliable, preventing determination of
the frequency of primary spheres. However, clonal density for.
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tions to be between 1 in 300 and 1 in 400 cells/cm2 (data not
shown). We next tested tumor-derived sphere growth in EGF
and bFGF. A significant increase in sphere formation (0.49% ±
0.17% versus 0.11% ± 0.01%; p < 0.01) was observed in me-
dium containing EGF and bFGF versus bFGF alone or medium
without growth factors (Figure 6E). Notably, the presence of
EGF alone promoted a significant increase in sphere formation,
demonstrating EGF dependence in this model, as in human
and embryonic spheres.
We then used RT-PCR to determine the developmental status
of sphere cells (Figures 6F–6H). GEM-neurofibroma spheres ex-
press transcripts characteristic of early crest cells (Snail, Slug,
Twist1, Nestin, Sox9, Sox10, and Wnt5a; Figure 6F), Schwann
cell precursors (Blbp, Dhh, and Ap2a), and mature Schwann
cells (Gfap,MPZ,MBP, andOct6); Figure 6G. Spheres do not ex-
press neuronal progenitor transcripts Ascl1 or Ngn1, or mature
peripheral neuron transcripts Phox2B and Brn3a (Figure 6H).
Figure 6. GEM-Neurofibroma from DhhCre;
Nf1fl/fl Mice Contain EGFR+;P75+ Cells and
Multipotent Progenitors
(A–C) Tumor sections contain P75 (green) and
EGFR (red) double-positive cells.
(D) Dissociated tumor cells form spheres in vitro.
(E) Sphere formation in the presence/absence of
EGF (20ng/ml),bFGF (20ng/ml), or the combination.
(F–N) RT-PCR showing neural crest (F) Schwann cell
(G), and neuronal (H) mRNA expression in spheres.
Sphere cells differentiate into neurons (I–K) as well
as glia and fibroblasts (L–N). Nuclei are stained
with DAPI (blue). Scale bars, (A)–(C), 10 mm; (D),
40 mm; (I)–(N), 130 mm. Data are shown as mean ±
standard error of the mean.
To determine the ability of sphere cells
to differentiate, we plated cells in serum
and identified neurons (b-tubulin+; neuro-
filament+; Figures 6I–6K) as well as
S100b+ glia and SMA+ SM/Fb-like cells
(Figures 6L–6N).
DISCUSSION
We describe a self-renewing, multipotent,
EGFR-dependent progenitor in the E12.5
mouse PNS (Figure 7A). Nf1 controls the
size of the progenitor pool and influences
its potential. Loss of Nf1 correlates with
growth of cells in immunocompromised
mice (Figure 7B). We identify EGFR+ cells
within human neurofibroma that form col-
onies and spheres, undergo multilineage
differentiation, and grow in nude mice,
and EGFR+ cells in DhhCre;Nf1fl/fl GEM-
neurofibromas that form EGFR-depen-
dent, multipotent spheres. We suggest
that this EGFR-dependent progenitor is
relevant to NF1 tumorigenesis.
Our data identify a normal EGF-dependent embryonic PNS
progenitor. DRG-derived spheres self-renew in an EGF-depen-
dent manner, and an inhibitor of EGFR activity blocks sphere for-
mation. Although erlotinib might also block the related receptor
ErbB2, we demonstrate the expression and activation of ErbB1
in sphere cells. Confirming relevance of EGFR activity, cells
from the Wa2 hypomorphic EGFR mutant show impaired sphere
formation. Wild-type andNf1/ cells each form clonally derived,
EGFR-dependent, self-renewing multipotent spheres. As multi-
potent sphere-forming cells have been identified in developing
(Bixby et al., 2002; Hagedorn et al., 1999; Morrison et al., 1999)
and adult PNS (Nagoshi et al., 2008), EGFR may help define
them. The presence of an EGFR-expressing cell at the Schwann
cell precursor stage of Schwann cell development E12.5 does
not exclude relevance of EGFR to earlier and/or later stages. In-
deed, GEM-neurofibromas show disruption of nonmyelin-form-
ing Schwann cells in Remak bundles (Ling et al., 2005; Zheng
et al., 2008; Wu et al., 2008). Some evidence supports anCell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 665
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(A) In the normal developmental situation, the neural crest gives rise to an EGFR+ cell found in the DRG at E12.5 in mouse, which is capable of Schwann cell, SM/
Fb-like cells, and rare neuronal differentiation.
(B) WhenNf1 is inactivated, this EGFR+ progenitor pool is amplified, neurogenesis is increased, and the population is tumorigenic. An EGFR+ cell can be identified
in the postnatal mutant nerve and in DhhCre;Nf1fl/fl GEM-neurofibroma. We propose that this EGFR+ tumor-derived progenitor models the P75+;EGFR+ multi-
potent, tumorigenic progenitor isolated from human primary neurofibroma.additional role for EGFR signaling in the perinatal period, via
mast cell recruitment, to this phenotype (Monk et al., 2007).
Nf1/ progenitors maintained a neurogenic bias over their
wild-type counterparts, consistent with loss of Nf1 causing sur-
vival and neurotrophin-independent neuronal differentiation
(Vogel et al., 1995). Nf1 mutation also expands the progenitor
population. While we were not able to cause cells to form mela-
nocytes, Nf1/;EGFR+;Blbp+ E12.5 DRG-derived embryonic
cells did form melanocytes in vivo (Rizvi et al., 2002). Strongly
supporting a role for an at least bipotent progenitor in human
NF1, identical biallelic NF1 mutations were identified in neurofi-
broma Schwann cells and melanocytes (Maertens et al., 2007).
Although we cannot exclude a contribution of increased
expression of EGFR ligand(s) expressed by Nf1/ cells to self-
renewal/expansion of the population, hyperresponse to mito-
gens (EGF, and to EGF plus bFGF) is likely to result from loss
of Nf1’s RAS-GAP function (Kim et al., 1995). Thus, Nf1/ blood
progenitors show Ras-dependent heightened response to gran-
ulocyte-macrophage colony-stimulating factor (Birnbaum et al.,
2000; Zhang et al., 1998).
We identified EGFR+;P75+ cells within human neurofibromas
that form spheres in vitro; FACS for EGFR and P75 enriched cells
capable of sphere formation. Cells with a propensity to form col-
onies in neurofibroma cultures had been noted, but not studied
(Muir et al., 2001). Human sphere cells are similar to mouse
EGFR+ sphere cells in their response to and dependence on
EGFR signaling, multipotency, and the ability to form subcutane-
ous benign lesions in nude mice. Mouse sphere cells grown as
subcutaneous xenografts also showed features of neurofi-
bromas, including S100b+ and S100b cells, occasional mast
cells, association with nerves and blood vessels, and no evi-666 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Incdence of malignancy. The data are consistent with our enriching
neurofibroma-initiating cells. Nf1/ midgestation neural crest
stem cells from E12.5 Nf1/ mouse DRG did not form neurofi-
bromas when injected into the nerve, possibly because nerve
injury associated with this procedure provided an unsuitable en-
vironment for tumorigenic progenitor survival or maintenance or
because of different culture conditions (Joseph et al., 2008).
Unlike mouse progenitors, human sphere-forming cultures
were not expandable at clonal density and depleted by passage
four. A possible trivial explanation for the limited clonogenic ca-
pacity of the human cell reflects lack of relevant cytokines
in vitro. Alternatively (and possibly relevant to the clinical obser-
vation of transient neurofibroma growth), the human cell may
have limited self-renewal because it is isolated after neurofi-
broma formation (Riccardi, 1992). We favor the idea that the hu-
man EGFR+;P75+ cell is a more committed, but not exclusive,
progenitor, rather than an earlier stem-like cell. This interpreta-
tion is consistent with the identification of cells expressing the
precursor marker AP-2a+ in human neurofibroma (Harder et al.,
2006) and our finding that BLBP is expressed by P75+;EGFR+
neurofibroma cells. Our finding that mouse DhhCre;Nf1fl/fl tu-
mors contain EGFR+;P75+ cells, and that dissociated tumor cells
are capable of sphere formation and multilineage differentiation,
also supports relevance of a similar progenitor population.
DhhCre;Nf1fl/fl GEM-neurofibroma spheres express transcripts
of multiple stages of glial development including the Schwann
cell precursor (Blbp and Ap2a). Dhhcre;Nf1fl/fl neurofibromas,
spheres derived from these neurofibromas, both wild-type and
Nf1/ spheres from E12.5 embryos, and spheres from human
neurofibromas all express EGFR and BLBP. These data provide
strong support for the idea that the tumor-initiating cell for human.
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pression of these markers. The data are supported by expres-
sion of desert hedgehog, an additional marker of BLBP progen-
itors, in mouse neurofibromas, spheres derived from these
neurofibromas, and both wild-type and Nf1/ spheres from
E12.5 embryos.
Other reports identify proliferating cells within GEM-neurofi-
broma and postnatal Nf1-deficient nerve as P75+ (neural crest,
precursor, nonmyelinating Schwann cell, and Schwann cell dis-
sociated from axon marker) or Gfap+ (Schwann cells dissociated
from axons and nonmyelinating Schwann cells) (Joseph et al.,
2008; Zheng et al., 2008). S100b+ (myelinating Schwann cell
and Schwann cells lacking axonal contact)/BrdU+ cells and
Blbp+ (progenitor) cells also occur in GEM-neurofibroma and
nerve (Wu et al., 2008). Thus, a panel of glial lineage markers is
expressed in the GEM-neurofibroma, possibly reflecting
stages of Schwann cell differentiation within the neurofibroma,
paralleling our finding that human neurofibromas contain
P75+;BLBP+;EGFR+ cells. As progenitors exist and nonmyelin-
ated fibers are disrupted within neurofibromas, we favor the
view that aberrant progenitors ultimately cause nonmyelinating
Schwann cell dysfunction.
A hierarchical model of tumor stem/progenitor cells has been
developed stating that cellular events at an early point in a lineage
allow for tumor formation as altered development proceeds.
Much about stem cell-initiated tumors has been learnt from the
hematopoietic system. For instance, chronic myeloproliferative
disorders are stem cell clonal disorders, resulting from mutations
that dysregulate key cellular proliferation pathways (e.g., BCR/
ABL or JAK2 mutants) (reviewed by Tefferi, 2008). These muta-
tions induce ‘‘benign’’ lineage-specific cell proliferation, which
themselves do not represent oncogenic transformation but
instead favor development of second hits that are the base of
malignant transformation into acute leukemias. Cancer stem/
progenitor cells have also been identified in solid tumor models
(Jordan et al., 2006). Our findings that progenitor cells can be
obtained from GEM-neurofibroma and human neurofibroma
support the hypothesis that these examples are relevant to
benign neurofibroma formation. The identification of an EGFR+
neurofibroma-initiating progenitor population provides an
avenue for study of the cellular biology of neurofibroma tumori-
genesis, enabling therapeutic targeting strategies.
EXPERIMENTAL PROCEDURES
Animals
We maintained mice per guidelines of the Animal Use and Care Committee at
the Cincinnati Children’s Hospital Medical Center. We mated Nf1+/ C57Bl/6
females (Brannan et al., 1994) with Nf1+/ 129X1/SvJ Nf1+/ males (Jackson;
Bar Harbor, ME). For timed dissections, the morning on which a vaginal plug
was observed was E0.5. DhhCre;Nf1fl/fl mice were generated as described
(Wu et al., 2008).
Sphere Culture
For primary cultures, we dissociated DRG from E12.5–13.5 embryos with
0.25% trypsin (Mediatech; Herndon, VA) for 20 min at 37C and obtained sin-
gle-cell suspensions with narrow-bore pipettes and a 40 mm strainer (BD-
Falcon). For postnatal mouse sciatic nerve dissection, we chopped tissue
into 1–3 mm3 pieces, plated in sphere medium for 3 days, centrifuged, and re-
suspended in L-15 (Mediatech) plus 0.5 mg/ml collagenase type I (Worthing-
ton; Lakewood, NJ), and 2.5 mg/ml dispase protease type II (Cambrex; EastCeRutherford, NJ) at 37C for 25 min. For all mouse cells, we used trypan blue
exclusion (Stem Cell Technologies, Vancouver, BC) to plate 2 3 104 live cells
per well in 24-well plates in sphere medium. Sphere medium (modified from
Fernandes et al., 2004) was as follows: DMEM:F-12 (3:1) + 20 ng/ml rhEGF
(R&D Systems), 20 ng/ml rh bFGF (R&D Systems), 1% B-27 (Invitrogen), and
2 mg/ml heparin (Sigma). We maintained cultures at 37C and 5% CO2
and counted floating spheres after 14 days. Half of the volume was removed
and replaced with fresh medium every 4 days, taking care to centrifuge
the used medium and collect any cells or spheres that may have been floating
to return to the plate. To passage, we centrifuged sphere cultures, treated with
0.05% trypsin-EDTA for 3 min, and dissociated and plated at 23 104 cells/ml
in 50% conditioned and 50% fresh medium. We counted secondary spheres
after 14 days. For EGFR inhibition experiments, erlotinib (Genentech; San
Francisco, CA) was dissolved in DMSO, added at 3 mM, and replenished in
fresh medium every 3 days. For each experiment, we show a representative
of more than three independent experiments.
Human Neurofibroma Culture
We obtained human plexiform neurofibromas incidental to therapeutic surgery
and after IRB approval. We cut tumors into 1 mm3 pieces in L-15 supple-
mented with Pen/Strep (Mediatech), gentomycin, collagenase type I, and dis-
pase protease II. We dissociated tumors at 37C for 4 hr. For sphere formation,
we plated 4 3 104 cells per well in 24-well plates and counted spheres after
21 days. Human sphere medium was DMEM/F-12 (1:1) + 1% N2 supplements,
1% B27, 20 ng/ml EGF, 20 ng/ml bFGF, 0.1 mM b-ME (Sigma), and 2 mg/ml
Heparin (Sigma). EGF and EGFR inhibitor application was as for mouse. The
monoclonal antibody Cetuximab was also used at 5 mg/ml (ImClone). For cul-
ture details, see Table S1. For immunocytochemistry, we seeded spheres onto
poly-L-lysine (PLL) and laminin-coated Lab-tek II tissue culture plates (Nalge
Nunc, Rochester, NY). Differentiation conditions were as for mouse.
CAFC Assay
We collected 6000 triple-positive cells and plated them at eight concentrations
(200 cells per well through 1.6 cells per well; 15 wells per dilution) to identify
hematopoietic progenitor and stem cells (Geiger et al., 2001). We scored for
clones three times per week for 7 weeks.
Mouse Neurofibroma Culture
DhhCre;Nf1fl/fl tumors were dissociated in the same manner as human tumors,
filtered with 40 micron cell strainers, and plated in mouse sphere medium; dif-
ferentiation and immunocytochemistry were conducted as above. Spheres
were dissociated as above and split after 10–14 days; feeding was the same
as for embryonic sphere cultures.
Lentiviral eGFP Generation and Infection
We produced lentivirus particles encoding GFP by transient cotransfection of
293T cells, as described (Arumugam et al., 2007). We dissociated spheres and
plated 1.0 3 103 cells in 96-well plates in 200 ml sphere proliferation medium.
After 24 hr, we removed growth medium, added a minimal volume (50–100 ml)
of purified virus at a moi of 10 and incubated at 37C. We removed virus-con-
taining medium the next day and applied fresh sphere medium.
Clonality Assay
We combined equal ratios of lentivirally labeled eGFP+ cells and unlabeled
cells from the same embryo and replated cells from dissociated mouse
spheres at limiting dilutions on PLL-coated chamber slides. We validated sin-
gle-cell plating. After 10 days, percentages of adherent single-color and mixed
spheres were scored. We dissociated and replated spheres from wells yielding
only single-color spheres. All samples gave rise to secondary spheres.
FACS Analysis
We incubated neurofibroma cell suspensions with mouse anti-human mono-
clonal antibodies against CD34 (8G12/HPCA-2, Becton Dickinson; San
Jose, CA) bound to allophycocyanin (APC), p75/NGFR (C40-1457, Becton
Dickinson) bound to phycoerythrin (PE), and EGFR (EGFR1, Research Diag-
nostics Inc; Flanders, NJ) bound to FITC and anti-CD16/CD32 antibody (Bec-
ton Dickinson) to block Fc g receptor unspecific binding, on ice in a solution
containing PBS/0.2% BSA/0.01% NaN3 for 30 min. After washing, well Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 667
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cin D (7-AAD, Invitrogen). We carried out isotipic controls with irrelevant mouse
IgG1-APC, mouse-IgG1-PE, and mouse IgG2b-FITC in parallel. We acquired
cell suspensions in a dual-laser (Argon 488 and dye laser 630 or HeNe 633)
FACSCalibur or FACSCanto (Becton Dickinson) and analyzed on an ‘‘alive’’
gate based on light scatter parameters and 7-AAD staining negativity. We
used the same incubation conditions to isolate cell populations (positive and
negative for the antigens CD34, p75/NGFR, and/or EGFR) by FACS. We
acquired cells in a FACSVantage DiVa equipped with a 488 nm Argon laser,
a 633 nm HeNe laser, and a tunable Argon-UV laser, sorting a total of 6 3 106
cells at one time.
In Vitro Differentiation
We plated DRG-derived spheres on PLL and laminin-coated chamber slides.
Base medium was DMEM: F-12 (3:1) + 10% FBS. For neurons, 40 ng/ml bFGF
was added for 5 days only, then 10 ng/ml each of NT-3, BDNF (R&D Systems),
and NGF (Harlan) was added for 7 days (Fernandes et al., 2004). For glia, 5 ng/ml
recombinant human b-heregulin and 2 mM forskolin (both R&D Systems) were
added for 10 days (Ratner et al., 2006). For smooth muscle fibroblasts, 40 ng/ml
bFGF was added for 5 days only, then 1 ng/ml TGF-b1 (Sigma-Aldrich) was
added for 7 days (Chen and Lechleider, 2004). For all conditions, we changed
medium every 3 days.
Immunocytochemistry
Following fixation, we permeablized cells with 0.2% TX 100 and blocked with
10% normal serum for 1 hr at room temperature. Primary antibodies were goat
anti-EGFR (Santa Cruz, SC-03-G, 1:10), rabbit anti-P75 (Chemicon 1:400),
mouse anti-b-tubulin (Chemicon 1:200), rabbit anti-S100b (DAKO 1:2000),
mouse anti-SMA (Sigma 1:500), and rabbit anti-NF-M (Chemicon, 1:200). Sec-
ondary incubations were with host-appropriate FITC or TRITC (Jackson Immu-
noresearch, West Grove, PA). We labeled nuclei with DAPI (Sigma-Aldrich,
St. Louis, MO). We acquired microscopic images with Openlab software suites
on a Zeiss Axiovert 200.
Tumorigenisis Assay in Nude Mice
We anaesthetized athymic nu/nu mice in isoflurane and subcutaneously in-
jected 1–4.5 3 105 mouse or human sphere cells per injection into left flanks.
Tumors were monitored weekly. We dissected visible tumors and fixed them in
4% paraformaldehyde overnight, then embedded in paraffin. We stained 6 mM
sections with hematoxylin and eosin, anti-S100b (1:2000, DAKO), and anti-
neurofilament (1:2000, Chemicon) visualized with HRP-conjugated goat anti-
rabbit antibody with diaminobenzidine reaction.
RT-PCR
We isolated total RNA from spheres (RNeasy Mini-Kit, QIAGEN) and made
cDNA (Superscript III RT, Invitrogen). We conducted RT-PCR as described
(Miller et al., 2003). Mouse sequences and protocols for Twist1, Nestin,
Wnt5a, P75, Sox9, and Mpz are published (Fernandes et al., 2004), as are
mouse Egfr (Represa et al., 2001), mouse and human BLBP (Miller et al.,
2003), and human P75 (Toma et al., 2005). Additional primer sequences are
shown in Table S2.
Statistics
All experiments were analyzed with a paired t test, and data are shown as
mean ± standard error of the mean.
SUPPLEMENTAL DATA
The Supplemental Data include two figures and two tables and can be found
with this article online at http://www.cellstemcell.com/supplemental/S1934-
5909(08)00526-2.
ACKNOWLEDGMENTS
We thank M. Nakafuku (Cincinnati Children’s Hospital Medical Center) for
numerous helpful suggestions, A. Stemmer-Rachamimov (Massachusetts
General Hospital) and M. Collins (Cincinnati Children’s) for assistance with pa-
thology, and B. Ehmer for assistance with confocal microscopy. We also thank668 Cell Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Incthe Cooperative Human Tissue Network for assistance in providing human
neurofibroma. This work was supported by National Institutes of Health
(NIH) R01-NS 28840 to N.R.
Received: December 8, 2006
Revised: September 9, 2008
Accepted: October 3, 2008
Published: December 3, 2008
REFERENCES
Aguirre, A., Rizvi, T.A., Ratner, N., and Gallo, V. (2005). Overexpression of the
epidermal growth factor receptor confers migratory properties to nonmigra-
tory postnatal neural progenitors. J. Neurosci. 25, 11092–11106.
Arumugam, P.I., Scholes, J., Perelman, N., Xia, P., Yee, J.K., and Malik, P.
(2007). Improved human beta-globin expression from self-inactivating lentivi-
ral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element.
Mol. Ther. 15, 1863–1871.
Baroffio, A., Dupin, E., and Le Douarin, N.M. (1988). Clone-forming ability and
differentiation potential of migratory neural crest cells. Proc. Natl. Acad. Sci.
USA 85, 5325–5329.
Birnbaum, R.A., O’Marcaigh, A., Wardak, Z., Zhang, Y.Y., Dranoff, G., Jacks,
T., Clapp, D.W., and Shannon, K.M. (2000). Nf1 and Gmcsf interact in myeloid
leukemogenesis. Mol. Cell 5, 189–195.
Bixby, S., Kruger, G.M., Mosher, J.T., Joseph, N.M., and Morrison, S.J. (2002).
Cell-intrinsic differences between stem cells from different regions of the
peripheral nervous system regulate the generation of neural diversity. Neuron
35, 643–656.
Brannan, C.I., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L., Reid,
S.W., Buchberg, A.M., Jenkins, N.A., Parada, L.F., and Copeland, N.G.
(1994). Targeted disruption of the neurofibromatosis type-1 gene leads to
developmental abnormalities in heart and various neural crest-derived tissues.
Genes Dev. 8, 1019–1029.
Burrows, R.C., Wancio, D., Levitt, P., and Lillien, L. (1997). Response diversity
and the timing of progenitor cell maturation are regulated by developmental
changes in EGFR expression in the cortex. Neuron 19, 251–267.
Carroll, S.L., and Ratner, N. (2008). How does the Schwann cell lineage form
tumors in NF1? Glia 56, 1590–1605.
Chen, S., and Lechleider, R.J. (2004). Transforming growth factor-beta-
induced differentiation of smooth muscle from a neural crest stem cell line.
Circ. Res. 94, 1195–1202.
DeClue, J.E., Heffelfinger, S., Benvenuto, G., Ling, B., Li, S., Rui, W., Vass,
W.C., Viskochil, D., and Ratner, N. (2000). Epidermal growth factor receptor
expression in neurofibromatosis type 1-related tumors and NF1 animal
models. J. Clin. Invest. 105, 1233–1241.
Doetsch, F., Petreanu, L., Caille, I., Garcia-Verdugo, J.M., and Alvarez-Buylla,
A. (2002). EGF converts transit-amplifying neurogenic precursors in the adult
brain into multipotent stem cells. Neuron 36, 1021–1034.
Dong, Z., Sinanan, A., Parkinson, D., Parmantier, E., Mirsky, R., and Jessen,
K.R. (1999). Schwann cell development in embryonic mouse nerves. J. Neuro-
sci. Res. 56, 334–348.
Fernandes, K.J., McKenzie, I.A., Mill, P., Smith, K.M., Akhavan, M., Barnabe-
Heider, F., Biernaskie, J., Junek, A., Kobayashi, N.R., Toma, J.G., et al. (2004).
A dermal niche for multipotent adult skin-derived precursor cells. Nat. Cell Biol.
6, 1082–1093.
Geiger, H., True, J.M., de Haan, G., and Van Zant, G. (2001). Age- and stage-
specific regulation patterns in the hematopoietic stem cell hierarchy. Blood 98,
2966–2972.
Hagedorn, L., Suter, U., and Sommer, L. (1999). P0 and PMP22 mark a multi-
potent neural crest-derived cell type that displays community effects in
response to TGF-beta family factors. Development 126, 3781–3794.
Harder, A., Mautner, V.F., Friedrich, R.E., Harder, T., Plagemann, A., and von
Deimling, A. (2006). Transcription factor AP-2 is expressed in human Schwann
cell-derived tumours. Histopathology 49, 441–443..
Cell Stem Cell
EGFR+ Progenitors in NeurofibromaHjerling-Leffler, J., Marmigere, F., Heglind, M., Cederberg, A., Koltzenburg,
M., Enerback, S., and Ernfors, P. (2005). The boundary cap: a source of neural
crest stem cells that generate multiple sensory neuron subtypes. Development
132, 2623–2632.
Ito, K., Morita, T., and Sieber-Blum, M. (1993). In vitro clonal analysis of mouse
neural crest development. Dev. Biol. 157, 517–525.
Jessen, K.R., and Mirsky, R. (2005). The origin and development of glial cells in
peripheral nerves. Natl. Rev. 6, 671–682.
Jordan, C.T., Guzman, M.L., and Noble, M. (2006). Cancer stem cells. N. Engl.
J. Med. 355, 1253–1261.
Joseph, N.M., Mukouyama, Y.S., Mosher, J.T., Jaegle, M., Crone, S.A., Dor-
mand, E.L., Lee, K.F., Meijer, D., Anderson, D.J., and Morrison, S.J. (2004).
Neural crest stem cells undergo multilineage differentiation in developing
peripheral nerves to generate endoneurial fibroblasts in addition to Schwann
cells. Development 131, 5599–5612.
Joseph, N.M., Mosher, J.T., Buchstaller, J., Snider, P., McKeever, P.E., Lim,
M., Conway, S.J., Parada, L.F., Zhu, Y., and Morrison, S.J. (2008). The loss
of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest
stem cells. Cancer Cell 13, 129–140.
Khalifa, M.A., Montgomery, E.A., Ismiil, N., and Azumi, N. (2000). What are the
CD34+ cells in benign peripheral nerve sheath tumors? Double immunostain-
ing study of CD34 and S-100 protein. Am. J. Clin. Pathol. 114, 123–126.
Kim, H.A., Rosenbaum, T., Marchionni, M.A., Ratner, N., and DeClue, J.E.
(1995). Schwann cells from neurofibromin deficient mice exhibit activation of
p21ras, inhibition of cell proliferation and morphological changes. Oncogene
11, 325–335.
Kleber, M., Lee, H.Y., Wurdak, H., Buchstaller, J., Riccomagno, M.M., Ittner,
L.M., Suter, U., Epstein, D.J., and Sommer, L. (2005). Neural crest stem cell
maintenance by combinatorial Wnt and BMP signaling. J. Cell Biol. 169,
309–320.
Lee, H.Y., Kleber, M., Hari, L., Brault, V., Suter, U., Taketo, M.M., Kemler, R.,
and Sommer, L. (2004). Instructive role of Wnt/beta-catenin in sensory fate
specification in neural crest stem cells. Science 303, 1020–1023.
Leimeroth, R., Lobsiger, C., Lussi, A., Taylor, V., Suter, U., and Sommer, L.
(2002). Membrane-bound neuregulin1 type III actively promotes Schwann
cell differentiation of multipotent Progenitor cells. Dev. Biol. 246, 245–258.
Lillien, L., and Wancio, D. (1998). Changes in epidermal growth factor receptor
expression and competence to generate glia regulate timing and choice of dif-
ferentiation in the retina. Mol. Cell. Neurosci. 10, 296–308.
Ling, B.C., Wu, J., Miller, S.J., Monk, K.R., Shamekh, R., Rizvi, T.A., De-
courten-Myers, G., Vogel, K.S., DeClue, J.E., and Ratner, N. (2005). Role for
the epidermal growth factor receptor in neurofibromatosis-related peripheral
nerve tumorigenesis. Cancer Cell 7, 65–75.
Lo, L., Dormand, E., Greenwood, A., and Anderson, D.J. (2002). Comparison of
the generic neuronal differentiation and neuron subtype specification func-
tions of mammalian achaete-scute and atonal homologs in cultured neural
progenitor cells. Development 129, 1553–1567.
Maertens, O., De Schepper, S., Vandesompele, J., Brems, H., Heyns, I., Jans-
sens, S., Speleman, F., Legius, E., and Messiaen, L. (2007). Molecular dissec-
tion of isolated disease features in mosaic neurofibromatosis type 1. Am. J.
Hum. Genet. 81, 243–251.
Maro, G.S., Vermeren, M., Voiculescu, O., Melton, L., Cohen, J., Charnay, P.,
and Topilko, P. (2004). Neural crest boundary cap cells constitute a source of
neuronal and glial cells of the PNS. Nat. Neurosci. 7, 930–938.
Miller, S.J., Li, H., Rizvi, T.A., Huang, Y., Johansson, G., Bowersock, J., Sidani,
A., Vitullo, J., Vogel, K., Parysek, L.M., et al. (2003). Brain lipid binding protein
in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Mol.
Cell. Biol. 23, 2213–2224.
Monk, K.R., Wu, J., Williams, J.P., Finney, B.A., Fitzgerald, M.E., Filippi, M.D.,
and Ratner, N. (2007). Mast cells can contribute to axon-glial dissociation and
fibrosis in peripheral nerve. Neuron Glia Biol. 3, 233–244.
Morrison, S.J., White, P.M., Zock, C., and Anderson, D.J. (1999). Prospective
identification, isolation by flow cytometry, and in vivo self-renewal of multipo-
tent mammalian neural crest stem cells. Cell 96, 737–749.CeMuir, D., Neubauer, D., Lim, I.T., Yachnis, A.T., and Wallace, M.R. (2001). Tu-
morigenic properties of neurofibromin-deficient neurofibroma Schwann cells.
Am. J. Pathol. 158, 501–513.
Nagoshi, N., Shibata, S., Kubota, Y., Nakamura, M., Nagai, Y., Satoh, E., Mor-
ikawa, S., Okada, Y., Mabuchi, Y., Katoh, H., et al. (2008). Ontogeny and multi-
potency of neural crest-derived stem cells in mouse bone marrow, dorsal root
ganglia, and whisker pad. Cell Stem Cell 2, 392–403.
Norman, P. (2001). OSI-774 OSI Pharmaceuticals. Curr. Opin. Investig. Drugs
2, 298–304.
Rasmussen, S.A., and Friedman, J.M. (2000). NF1 gene and neurofibroma-
tosis 1. Am. J. Epidemiol. 151, 33–40.
Ratner, N., Williams, J.P., Kordich, J.J., and Kim, H.A. (2006). Schwann cell
preparation from single mouse embryos: analyses of neurofibromin function
in Schwann cells. Methods Enzymol. 407, 22–33.
Represa, A., Shimazaki, T., Simmonds, M., and Weiss, S. (2001). EGF-respon-
sive neural stem cells are a transient population in the developing mouse spinal
cord. Eur. J. Neurosci. 14, 452–462.
Reynolds, B.A., and Weiss, S. (1992). Generation of neurons and astrocytes
from isolated cells of the adult mammalian central nervous system. Science
255, 1707–1710.
Riccardi, V. (1992). Neurofibromatosis: Phenotype, Natural History, and Path-
ogenesis (Baltimore: John Hopkins University Press).
Rizvi, T.A., Huang, Y., Sidani, A., Atit, R., Largaespada, D.A., Boissy, R.E., and
Ratner, N. (2002). A novel cytokine pathway suppresses glial cell melanogen-
esis after injury to adult nerve. J. Neurosci. 22, 9831–9840.
Serra, E., Ars, E., Ravella, A., Sanchez, A., Puig, S., Rosenbaum, T., Estivill, X.,
and Lazaro, C. (2001). Somatic NF1 mutational spectrum in benign neurofi-
bromas: mRNA splice defects are common among point mutations. Hum.
Genet. 108, 416–429.
Shah, N.M., Groves, A.K., and Anderson, D.J. (1996). Alternative neural crest
cell fates are instructively promoted by TGFb superfamily members. Cell 85,
331–343.
Sieber-Blum, M., Grim, M., Hu, Y.F., and Szeder, V. (2004). Pluripotent neural
crest stem cells in the adult hair follicle. Dev. Dyn. 231, 258–269.
Stemple, D.L., and Anderson, D.J. (1992). Isolation of a stem cell for neurons
and glia from the mammalian neural crest. Cell 71, 973–985.
Tefferi, A. (2008). The history of myeloproliferative disorders: before and after
Dameshek. Leukemia 22, 3–13.
Toma, J.G., McKenzie, I.A., Bagli, D., and Miller, F.D. (2005). Isolation and
characterization of multipotent skin-derived precursors from human skin.
Stem Cells 23, 727–737.
Vogel, K.S., Brannan, C.I., Jenkins, N.A., Copeland, N.G., and Parada, L.F.
(1995). Loss of neurofibromin results in neurotrophin-independent survival of
embryonic sensory and sympathetic neurons. Cell 82, 733–742.
Wu, J., Crimmins, J.T., Monk, K.R., Williams, J.P., Fitzgerald, M.E., Tedesco,
S., and Ratner, N. (2006). Perinatal epidermal growth factor receptor blockade
prevents peripheral nerve disruption in a mouse model reminiscent of benign
world health organization grade I neurofibroma. Am. J. Pathol. 168, 1686–
1696.
Wu, J., Williams, J.P., Rizvi, T.A., Kordich, J.J., Witte, D., Meijer, D., Stemmer-
Rachamimov, A.O., Cancelas, J.A., and Ratner, N. (2008). Plexiform and
dermal neurofibromas and pigmentation are caused by Nf1 loss in desert
hedgehog-expressing cells. Cancer Cell 13, 105–116.
Zhang, Y.Y., Vik, T.A., Ryder, J.W., Srour, E.F., Jacks, T., Shannon, K., and
Clapp, D.W. (1998). Nf1 regulates hematopoietic progenitor cell growth and
ras signaling in response to multiple cytokines. J. Exp. Med. 187, 1893–1902.
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D.K., and Zhu, Y.
(2008). Induction of abnormal proliferation by nonmyelinating Schwann cells
triggers neurofibroma formation. Cancer Cell 13, 117–128.
Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K., and Parada, L.F. (2002). Neuro-
fibromas in NF1: Schwann cell origin and role of tumor environment. Science
296, 920–922.ll Stem Cell 3, 658–669, December 4, 2008 ª2008 Elsevier Inc. 669
